151 related articles for article (PubMed ID: 17926052)
21. MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.
Kontogeorgos G; Thodou E; Koutourousiou M; Kaltsas G; Seretis A
Pituitary; 2019 Dec; 22(6):614-619. PubMed ID: 31571099
[TBL] [Abstract][Full Text] [Related]
22. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
[TBL] [Abstract][Full Text] [Related]
23. Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities.
Kontogeorgos G; Thodou E
Hormones (Athens); 2019 Dec; 18(4):333-337. PubMed ID: 31721137
[No Abstract] [Full Text] [Related]
24. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
Salehi F; Scheithauer BW; Kovacs K; Horvath E; Syro LV; Sharma S; Manoranjan B; Cusimano M
Neurosurgery; 2012 Feb; 70(2):491-6; discussion 496. PubMed ID: 21822153
[TBL] [Abstract][Full Text] [Related]
25. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
26. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
Raverot G; Castinetti F; Jouanneau E; Morange I; Figarella-Branger D; Dufour H; Trouillas J; Brue T
Clin Endocrinol (Oxf); 2012 Jun; 76(6):769-75. PubMed ID: 22404748
[TBL] [Abstract][Full Text] [Related]
27. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Widhalm G; Wolfsberger S; Preusser M; Woehrer A; Kotter MR; Czech T; Marosi C; Knosp E
Cancer; 2009 Mar; 115(5):1070-80. PubMed ID: 19156926
[TBL] [Abstract][Full Text] [Related]
28. Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine?
Shacham-Shmueli E; Beny A; Geva R; Blachar A; Figer A; Aderka D
J Clin Oncol; 2011 Apr; 29(10):e262-5. PubMed ID: 21220612
[No Abstract] [Full Text] [Related]
29. DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Chen YP; Hou XY; Yang CS; Jiang XX; Yang M; Xu XF; Feng SX; Liu YQ; Jiang G
Tumour Biol; 2016 Aug; 37(8):11209-18. PubMed ID: 26943799
[TBL] [Abstract][Full Text] [Related]
30. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
McCormack AI; Wass JA; Grossman AB
Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
[TBL] [Abstract][Full Text] [Related]
31. Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
Boeckmann L; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Struever D; Emmert S
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):33-5. PubMed ID: 19203531
[No Abstract] [Full Text] [Related]
32. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
Amatu A; Sartore-Bianchi A; Moutinho C; Belotti A; Bencardino K; Chirico G; Cassingena A; Rusconi F; Esposito A; Nichelatti M; Esteller M; Siena S
Clin Cancer Res; 2013 Apr; 19(8):2265-72. PubMed ID: 23422094
[TBL] [Abstract][Full Text] [Related]
33. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents.
Szeliga M; Zgrzywa A; Obara-Michlewska M; Albrecht J
J Neurochem; 2012 Nov; 123(3):428-36. PubMed ID: 22888977
[TBL] [Abstract][Full Text] [Related]
34. Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
Caporaso P; Turriziani M; Venditti A; Marchesi F; Buccisano F; Tirindelli MC; Alvino E; Garbin A; Tortorelli G; Toppo L; Bonmassar E; D'Atri S; Amadori S
DNA Repair (Amst); 2007 Aug; 6(8):1179-86. PubMed ID: 17500047
[TBL] [Abstract][Full Text] [Related]
35. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
McCormack A; Dekkers OM; Petersenn S; Popovic V; Trouillas J; Raverot G; Burman P;
Eur J Endocrinol; 2018 Mar; 178(3):265-276. PubMed ID: 29330228
[TBL] [Abstract][Full Text] [Related]
36. MGMT expression and pituitary tumours: relationship to tumour biology.
McCormack A; Kaplan W; Gill AJ; Little N; Cook R; Robinson B; Clifton-Bligh R
Pituitary; 2013 Jun; 16(2):208-19. PubMed ID: 22797801
[TBL] [Abstract][Full Text] [Related]
37. O6-Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry.
Buccoliero AM; Castiglione F; Rossi Degl'Innocenti D; Paglierani M; Maio V; Gheri CF; Garbini F; Moncini D; Taddei A; Sardi I; Sanzo M; Giordano F; Mussa F; Genitori L; Taddei GL
J Chemother; 2008 Apr; 20(2):263-8. PubMed ID: 18467255
[TBL] [Abstract][Full Text] [Related]
38. MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Everhard S; Kaloshi G; Crinière E; Benouaich-Amiel A; Lejeune J; Marie Y; Sanson M; Kujas M; Mokhtari K; Hoang-Xuan K; Delattre JY; Thillet J
Ann Neurol; 2006 Dec; 60(6):740-3. PubMed ID: 17192931
[TBL] [Abstract][Full Text] [Related]
39. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Bracht LK; Wen P; Meyerhardt JA; Kulke MH; Hornick JL; Redston M; LaFrankie DC; Black PM; Kesari S; Norden A; Drappatz J
J Clin Oncol; 2008 Oct; 26(29):4843-4. PubMed ID: 18779600
[No Abstract] [Full Text] [Related]
40. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]